Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Boric Acid SCHEMBL28285073 | 1.00 | THRB (0.43) | THRBTSHRLMNATDP1ALDH1A1 | |
| Boric Acid SCHEMBL17962526 | 1.00 | THRB (0.43) | THRBTSHRLMNATDP1ALDH1A1 | |
| Boric Acid SCHEMBL4976220 | 1.00 | THRB (0.43) | THRBTSHRLMNATDP1ALDH1A1 | |
| Boric Acid SCHEMBL594481 | 1.00 | THRB (0.43) | THRBTSHRLMNATDP1ALDH1A1 | |
| Boric Acid SCHEMBL474845 | 1.00 | THRB (0.43) | THRBTSHRLMNATDP1ALDH1A1 | |
| Boric Acid SCHEMBL28194459 | 0.95 | THRB (0.40) | THRBTSHRLMNATDP1ALDH1A1 | |
| Boric Acid SCHEMBL28207524 | 0.95 | THRB (0.40) | THRBTSHRLMNATDP1ALDH1A1 | |
| Boric Acid SCHEMBL28230424 | 0.95 | THRB (0.40) | THRBTSHRLMNATDP1ALDH1A1 | |
| Boric Acid SCHEMBL27938813 | 0.91 | THRB (0.38) | THRBTSHRLMNATDP1 | |
| Benzene SCHEMBL6931516 | 0.88 | THRB (0.35) | THRBTSHRLMNATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119948027-A | SOS1 protein degradation agent and application thereof | 领泰生物医药(绍兴)有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-115232108-B | SOS1 degradation agent and preparation method and application thereof | 领泰生物医药(绍兴)有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-115677569-B | Synthesis method of pyridines and substituted benzenes based on reduction coupling reaction of iron-catalyzed aryl halide and alkyl halide | 重庆大学 | 2024-05-28 | — | — | CN | disclosed |
| CN-117603105-A | Method for iron-catalyzed non-activated olefin selective difunctional reaction | 甘肃泰友生物科技有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-112839931-B | 1,2,3, 4-tetrahydroquinoxaline derivative, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-110740991-B | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2023-07-04 | — | — | CN | disclosed |
| CN-112601745-B | Azaaryl amide derivative and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20090137566-A1 | Substituted Piperdines as Renin Inhibitors | EHARA TAKERU | 2009-05-28 | — | — | US | disclosed |
| EP-1888569-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006125621-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137566-A1 | Substituted Piperdines as Renin Inhibitors | REN, ACE, AGTR1 | THRB 1495/4885TSHR 1818/4885LMNA 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.